Source comparison
Peptides for ACL Recovery: Protocol Comparison
BPC-157 VEGF upregulation, collagen type I synthesis, fibroblast proliferation 250–500 mcg/day subcutaneous, weeks 2–12 Proliferative (weeks 2–12) Rodent ligament studies show 30–40% faster healing; no human RCTs Strongest mechanistic evidence for collagen rem
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, collagen type I synthesis, fibroblast proliferation
- 250–500 mcg/day subcutaneous, weeks 2–12
- Proliferative (weeks 2–12)
- Rodent ligament studies show 30–40% faster healing; no human RCTs
- Strongest mechanistic evidence for collagen remodeling acceleration
- TB-500
- Actin regulation, endothelial cell migration, angiogenesis
- 2–5 mg twice weekly (weeks 0–4), then 2 mg weekly (weeks 5–12)
- Inflammatory and early proliferative (weeks 0–6)
- Animal tendon studies; limited ACL-specific data
- Best suited for early vascularization phase
- MK-677
- Growth hormone secretagogue, IGF-1 elevation
- 10–25 mg/day oral
- Entire recovery timeline
- Increases IGF-1 by 40–90%; indirect collagen synthesis support
- Systemic anabolic support; not ACL-specific
- Collagen peptides (Type I/III)
- Provides amino acid substrate for collagen synthesis
- 10–20 g/day oral
- Human studies show improved tendon stiffness; no ACL-specific trials
- Nutritional support; does not accelerate fibroblast activity